Navigation Links
Clinical Proof of Concept for TGF-beta 2-Inhibitor AP 12009 in Phase Iib EMEA provides Guidance on Phase III Design and Approval Requirements
Date:6/2/2008

or 10 μM AP 12009 in recurrent or refractory anaplastic astrocytoma, with up to 42% at 14 months. At the same time, the initial 25%-overall response rate in the control group fell to zero.

An international, randomized, active-controlled, Phase III study to evaluate the efficacy and safety of AP 12009 as monotherapy in adult patients with recurrent or refractory anaplastic astrocytoma will start in Q3 2008. The study drug will be compared to standard chemotherapy with either Temozolomide or BCNU. Antisense Pharma plans to conduct an interim analysis using the progression rate at 14 months as the surrogate endpoint. Positive results will allow submission for conditional approval by the EMEA. The SAWP at the EMEA indicated that, due to the rarity of the disease, the surrogate endpoint would be accepted, provided that the response data are supported by survival data. The fixed timepoint analysis at 24 months will be acceptable as the primary endpoint for full approval. Furthermore, a time-to-event analysis will be performed. "We are very pleased with this explicit statement by the Scientific Advice Working Party to proceed as we have planned. We sincerely hope that this will accelerate access to treatment for patients in need," says Dr. Hubert Heinrichs, Chief Medical Officer of Antisense Pharma. The Phase III study aims to enroll recurrent or refractory anaplastic astrocytoma patients in about 50 centers in 12 countries.

In the international randomized, active-controlled Phase IIb study, reported at ASCO, recurrent or refractory glioblastoma patients also showed long-lasting tumor responses in the AP 12009 groups (2). As of April 2008 the odds ratio for 10 μM AP 12009 versus control is 0.54. The risk to die is thus reduced by approximately 50% for glioblastoma patients receiving the study drug, as compared to patients under standard chemotherapy treatment. "Based on these data, a pivotal clinical trial in glioblastoma patients with good prognosis, for e
'/>"/>

SOURCE Antisense Pharma GmbH
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
2. Jazz Pharmaceuticals, Inc. Completes Enrollment in First of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
3. New Nexavar Data Presented in Multiple Tumor Types at 44th American Society of Clinical Oncology Annual Meeting
4. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
5. Preliminary Data from Ongoing Phase 1 Data of Investigational Anti-PD-1 Antibody Presented at American Society of Clinical Oncology Annual Meeting
6. CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma
7. BioVex Reports Positive Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting
8. Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma
9. Exelixis Reports Positive Clinical Pharmacodynamics Data for PI3K/mTOR Inhibitor XL765 at ASCO
10. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
11. About 60 Clinical Studies Regarding Schering-Ploughs Oncology Compounds Will be Presented at ASCO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... 2014  New data demonstrates that flibanserin, a novel, ... of female sexual dysfunction, Hypoactive Sexual Desire Disorder (HSDD), ... in premenopausal women when taken at bedtime. The data ... North America,s (SMSNA) 20th Annual Fall ... SMSNA accepted this study as a late ...
(Date:11/22/2014)... -- Statistics released from a number of organizations show ... the holidays, beginning with Thanksgiving eve, which is now ... The data, highlighted in an Infographic released ... their annual Sober Days for the Holidays public ... and increased rates of DUI injuries and deaths during ...
(Date:11/22/2014)... 2014 Many power shifts are occurring ... of patients in the biopharmaceutical market is impacting ... than ever, understanding how to effectively acquire, convert, ... essential. According to recent research ... spent about two-thirds of their patient-focused dollars on ...
Breaking Medicine Technology:Study on Efficacy and Sedation-Related Safety of Flibanserin in Premenopausal Women Released Today at Sexual Medicine Society of North America Meeting 2Study on Efficacy and Sedation-Related Safety of Flibanserin in Premenopausal Women Released Today at Sexual Medicine Society of North America Meeting 3Alarming Stats Show Holiday Drinking an Issue for Many 2New Report Details Importance of Adopting a "Patient Journey" Framework in Marketing 2
... Food and Drug,Administration (FDA) today proposed that makers ... warning on,their products' labeling to include warnings about ... suicidality, in young,adults ages 18 to 24 during ... , The proposed labeling changes also include language ...
... England, 26th April 2007 - CeNeS Pharmaceuticals plc,(LSE: ... the United States Food and Drug Administration (FDA),has ... the,clinical development of morphine-6-glucuronide (M6G), its novel,drug for ... announced results of a Phase III study of ...
Cached Medicine Technology:FDA Proposes New Warnings About Suicidal Thinking, Behavior in,Young Adults Who Take Antidepressant Medications 2FDA Proposes New Warnings About Suicidal Thinking, Behavior in,Young Adults Who Take Antidepressant Medications 3FDA approves IND on Lead Product M6G 2
(Date:11/24/2014)... November 24, 2014 From embedded sensors and ... of fitness technology will take center stage at the ... at the 2015 International CES® , January 6, ... Level 2, Bellini 2004). The bond between fitness and technology ... less about devices and more about the human body. , ...
(Date:11/24/2014)... 24, 2014 Abington Health ... has joined The Neurology Group and has been ... Center. , A graduate of Vinnica Medical University ... Albert Einstein Medical Center in Philadelphia and completed a ... Sclerosis Center at Weill Cornell Medical College. Ternopolska is ...
(Date:11/24/2014)... New York (PRWEB) November 24, 2014 ... contacted by the Family and Children's Association ... such as soap, shampoo, mouthwash and other such items.The ... citizens who are home bound, living in nursing homes, ... intended to greatly enhance the well being of seniors ...
(Date:11/24/2014)... (PRWEB) November 24, 2014 ReAdmission ... and disease management services to health plans, hospitals, ... Essette’s Medical Management software suite. ReAdmission Solutions ... in a program to reduce patients' avoidable readmissions ... Health Management, Care Management, Utilization Management, and Appeals ...
(Date:11/23/2014)... well-known wedding dress manufacturer, has unveiled its new collection of ... offered at deeply discounted prices, up to 75 percent off. ... The main purpose of the promotion is to expand iFitDress.com’s ... ideal options for ladies who are eager to look charming ... mint cocktail dresses are very beautiful; they are made with ...
Breaking Medicine News(10 mins):Health News:Next Wave Fitness Products Debut at FitnessTech Summit Living in Digital Times at the 2015 International CES 2Health News:Next Wave Fitness Products Debut at FitnessTech Summit Living in Digital Times at the 2015 International CES 3Health News:Next Wave Fitness Products Debut at FitnessTech Summit Living in Digital Times at the 2015 International CES 4Health News:Nataliya Ternopolska Named Associate Medical Director of Abington Health’s Multiple Sclerosis Center 2Health News:The Holiday Inn Westbury - Long Island gives back to the local Long Island community, and also goes beyond borders to assist those in need during the 2014 Holiday Season 2Health News:The Holiday Inn Westbury - Long Island gives back to the local Long Island community, and also goes beyond borders to assist those in need during the 2014 Holiday Season 3Health News:ReAdmission Solutions, LLC Selects Essette 2Health News:Trendy Long Black Evening Gowns Now Provided By iFitDress.com 2
... women expect to go through common symptoms during pregnancy, such as morning ... to deal with them when they come. At Gurgle, we offer a ... cope with these symptoms. , ... London, England (PRWEB) April 2, 2009 ...
... symptoms of the autistic condition Asperger Syndrome, such as a ... to levels of the stress hormone cortisol, suggests new research ... a surge of this hormone shortly after waking, with levels ... makes the brain alert, preparing the body for the day ...
... social care services face a host of new challenges ... personal budgets* in social care. The issues raised for ... are outlined in ,The impact of personal budgets on ... booklet highlights the views of leading experts on social ...
... and San DiegoST. JOSEPH, Mo., April 1 This spring, ... pets, hearts checked is a walk in the park. ... make stops in April 4 and 5 with a sound-proof ... perform free heart examinations of area dogs.In addition to performing ...
... Susan G. Komen Detroit Race for the ... Ann Karmanos Cancer Institute, join other Komen Affiliates ... applaud the introduction of the 21st Century Cancer ... Treatment) Act, bipartisan legislation co-sponsored by Sens. Edward ...
... ADDISON, Texas, April 1 ULURU ... announced today that clinical evidence on the treatment ... the physical properties of Altrazeal(TM) Silver will be presented at ... 2009. The work will be presented in podium presentations ...
Cached Medicine News:Health News:Gurgle's Guide on How to Beat Morning Sickness and Pregnancy Fatigue 2Health News:Gurgle's Guide on How to Beat Morning Sickness and Pregnancy Fatigue 3Health News:Gurgle's Guide on How to Beat Morning Sickness and Pregnancy Fatigue 4Health News:Gurgle's Guide on How to Beat Morning Sickness and Pregnancy Fatigue 5Health News:Autism linked with stress hormone levels 2Health News:Third sector gears up to meet 2Health News:Third sector gears up to meet 3Health News:Mobile Dog Heart Health Tour Through California Cities to Provide Free Heart Examinations in Sound-Proof Setting 2Health News:Mobile Dog Heart Health Tour Through California Cities to Provide Free Heart Examinations in Sound-Proof Setting 3Health News:Komen Detroit and the Karmanos Cancer Institute Applaud Introduction of Bipartisan Cancer Alert Act 2Health News:Komen Detroit and the Karmanos Cancer Institute Applaud Introduction of Bipartisan Cancer Alert Act 3Health News:Komen Detroit and the Karmanos Cancer Institute Applaud Introduction of Bipartisan Cancer Alert Act 4Health News:Altrazeal(TM) Clinical Evidence to be Presented at The American Professional Wound Care Association (APWCA) National Clinical Conference 2009 2Health News:Altrazeal(TM) Clinical Evidence to be Presented at The American Professional Wound Care Association (APWCA) National Clinical Conference 2009 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: